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There has been little investigation of the effects of past substance abuse (SA) on working memory (WM) impairments in schizophrenia. This study examined the behavioral and
neurobiological impact of past SA (6 months or longer abstinence period) on WM in schizophrenia. Thirty-seven schizophrenia patients (17 with past SA and 20 without) and 32
controls (12 with past SA and 20 without) completed two versions of a two-back WM task
during fMRI scanning on separate days. Analyses focused on regions whose patterns of
activation replicated across both n-back tasks. Schizophrenia patients were significantly
less accurate than controls on both n-back tasks. No main effects or interactions with
past SA on WM performance were observed. However, several fronto-parietal-thalamic
regions showed an interaction between diagnostic group and past SA. These regions were
significantly more active in controls with past SA compared to controls without past SA.
Schizophrenia patients with or without past SA either showed no significant differences, or
patients with past SA showed somewhat less activation compared to patients without past
SA during WM. These results suggest robust effects of past SA on WM brain functioning
in controls, but less impact of past SA in schizophrenia. This is consistent with previous
literature indicating less impaired neurocognition in schizophrenia with SA.
Keywords: schizophrenia, substance abuse, n-back, working memory, fMRI, neurocognition

INTRODUCTION
The lifetime prevalence rate of substance abuse (SA) among
patients diagnosed with schizophrenia is approximately 50% (1).
Despite the extent of SA in schizophrenia, neurocognitive (2, 3)
and neuroimaging (4) evidence of the impact of past SA in this
illness has been relatively inconsistent. These studies have primarily focused on patients either currently using substances or
recently abstinent from SA. While understanding acute effects
are important, it is also critical to determine whether past SA
has any lasting effects on neurocognitive and/or neurobiological functioning in schizophrenia. Examining the impact of past
SA on working memory (WM) in schizophrenia patients is vital,
given the evidence for long-term WM impairments persisting after
long-term abstinence from SA in non-psychosis samples (5–14). It
is also well known that schizophrenia patients are burdened with
robust deficits in WM performance (15) and brain functioning
(16). Therefore, investigation of possible residual effects of past
SA on WM impairments could provide further understanding of
the complex interaction between neurocognitive impairment and
SA in schizophrenia, and could have implications for prevention
and intervention in cognitive impairments in schizophrenia.
Several studies have shown a negative impact of past SA on
WM brain functioning in non-psychosis samples. After 28 days of
abstinence, adolescent marijuana users displayed aberrant brain
activations evoked during WM in the dorsolateral prefrontal
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cortex (DLPFC), parietal cortex, and occipital regions compared
to non-abusers (17). Altered WM-related activation patterns in
frontal–parietal and cerebellar regions have been observed in males
with prior alcoholism compared to healthy males (18, 19). Tomasi
and colleagues (20) revealed residual negative effects of cocaine
on brain functioning in dopaminergic-regulated brain regions
in abstinent cocaine abusers while engaged in WM. While these
aforementioned studies did not focus on schizophrenia-spectrum
comorbidity, their results indicate functional WM impairments
associated with past SA, even after long-term abstinence.
Despite the aforementioned neurobiological evidence for residual WM deficits associated with past SA in non-psychosis samples,
relatively few research studies exist examining these effects in
schizophrenia. The current literature has mixed results that are
somewhat difficult to interpret (21). Starting with the behavioral
performance literature, an additional SA diagnosis in schizophrenia did not exacerbate WM impairments compared to patients
without past SA (22). Rodriguez-Jimenez and others (23) also
found no differences in executive function between schizophrenia patients with and without past SA; although the predictors
of poorer executive function did differ. Past cannabis abuse has
been generally associated with similar or better neurocognition
in patients with schizophrenia compared to patients without past
cannabis abuse (2, 3, 24, 25). A history of alcoholism in schizophrenia has also been shown to not convey an additional burden
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on neurocognitive impairments (26). However, Allen and colleagues (27) observed an association between past alcohol abuse
and cognitive–perceptual neurologic dysfunction in schizophrenia patients. Past and current cocaine dependent schizophrenia
patients have been shown to not significantly differ in neurocognitive deficits (28). However, other work has shown that past
cocaine abuse and dependence exacerbated memory and learning impairments in schizophrenia with and without past cocaine
use (29, 30).
An interesting differential effect of past SA on neurocognitive functioning in schizophrenia patients compared to controls
has been recently observed. Jockers-Scherübl and colleagues (31)
found that controls with past cannabis abuse displayed decreased
neurocognitive functioning compared to controls without past
cannabis abuse. Conversely, schizophrenia patients with past
cannabis abuse had slightly better neurocognitive functioning
compared to patients without past cannabis abuse. Donoghue
and others (32) also found first-episode schizophrenia patients
with and without past SA performed similarly on neurocognitive assessments, while the controls with past SA performed more
poorly on measures of WM and executive function compared
to controls without past SA. Taken together, clear inferences are
difficult to make regarding the impact of past SA (short or longterm) on neurocognitive functioning in schizophrenia. Further,
two recent meta-analyses concluded that these mixed findings
may be accounted for by heterogeneous variables in schizophrenia samples studied such as age, type of SA, and status of abuse
(2, 3).
There are also fairly limited and mixed findings with regard
to the effects of past SA on indices of brain structure and function in schizophrenia. To our knowledge, there have been no
fMRI investigations of SA-related WM deficits in schizophrenia.
Two social–cognitive fMRI studies indicated that schizophrenia
patients with past SA had relatively preserved medial prefrontal
cortex activity during processing of social emotion (33) and affect
regulation (34) compared to patients without past SA. Similar to
the differential impact of past SA on neurocognition in schizophrenia and controls discussed above, Rentzsch and colleagues (35)
observed a P50 sensory gating deficit, measured by EEG, only in
the controls with past cannabis abuse compared to controls without past cannabis abuse. Schizophrenia patients with and without
past cannabis abuse did not significantly differ in P50 sensory
gating. In contrast, Thoma and colleagues (36) found that schizophrenia patients with a history of alcohol abuse had the greatest
deficits in WM and P50 sensory gating compared to schizophrenia
patients without past alcohol abuse and controls with and without
past alcohol abuse.
A review of the SA neuroimaging literature by Potvin and colleagues (4) suggested some evidence for exacerbated structural
abnormalities associated with alcohol and cannabis use in schizophrenia. In a voxel-based morphometry investigation, schizophrenia patients with past SA were found to have gray matter volume
decreases in the anterior cingulate and frontopolar areas associated with impulsivity compared to non-abusing schizophrenia
(37). Additionally, relative to patients without past SA, previous exposure to cannabis (38, 39) and alcohol (40–42) has been
associated with worsened structural abnormalities in cingulate,
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subcortical (e.g., hippocampus, striatum, and thalamus), and cerebellar regions in schizophrenia patients with past SA. In contrast,
other studies have demonstrated that schizophrenia patients with
past SA have qualitatively less structural MRI anomalies compared
to patients without past SA (43).
As described above, there is limited and mixed evidence regarding the impact of past SA on WM functioning in schizophrenia.
Thus, the aim of this investigation was to do an initial examination of the impact of past SA on brain activation during WM
performance in schizophrenia patients with and without past
SA compared to healthy controls with and without past SA. To
increase confidence in our findings through replication, participants completed one version of a two-back WM task during
one scanning session and then completed a second version of
a two-back WM task during a second scanning session on a
different day. Given the inconsistent results in the prior literature, it is difficult to make specific predictions about the behavioral and functional impairments associated with 6 months or
longer abstinence periods in the schizophrenia patients. However, the literature suggesting detrimental effects of past SA on
WM performance and brain activation in non-psychosis samples
leads us to hypothesize that schizophrenia patients with past SA
will display the greatest degree of WM impairments in performance and brain activation in regions implicated in WM impairment, such as the DLPFC (44) and other frontal and cingulate
regions (6).

MATERIALS AND METHODS
PARTICIPANTS

Participants were recruited through the clinical core of the Conte
Center for the Neuroscience of Mental Disorders (CCNMD) at
Washington University in St. Louis. Exclusion criteria included:
(a) any type of substance abuse/dependence present within the
past 6 months; (b) the presence of any clinically unstable or severe
medical disorder; (c) current or past head injury with documented
neurological sequelae, and/or causing loss of consciousness; (d)
meeting DSM-IV criteria for mental retardation; and (e) pregnancy, or any contraindication to MR. Controls were excluded if
they had any lifetime history of, or first-order family member with,
an Axis I psychotic disorder. Controls were also excluded if they
endorsed any personal current or past mood or anxiety disorder
other than specific phobias.
A total of 37 participants with DSM-IV-TR schizophrenia (17
with past SA and 20 without) and 32 controls (12 with past SA
and 20 without) completed the n-back version A task. Thirtyone of the above schizophrenia participants (15 with past SA
and 16 without) and 29 control participants (17 with past SA
and 12 without) also completed the n-back version B task on
a different scanning day. Fewer subjects completed the n-back
version B task because they failed to return to the second scanning session on a different day. All participants provided written informed consent in accordance with Washington University
Human Subjects Committee’s criteria. Schizophrenia diagnoses
were based on a Structured Clinical Interview for DSM-IV-TR
(45) performed by a trained masters-level clinician. The clinician also had access to past and present medical records and to
corroborative personal sources (e.g., family), and combined all
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data to arrive at a diagnosis. This rater regularly participated
in clinical interview and reliability training sessions as part of
the CCNMD. Clinical symptoms were rated using the Scale for
the Assessment of Positive Symptoms [SAPS; (46)] and Negative
Symptoms [SANS; (46)]. Based on previous factor analytic studies
of the SAPS/SANS (47), we created the following symptom domain
scores: (1) positive symptoms – hallucinations and delusions; (2)
negative symptoms – alogia, anhedonia, avolition, affective flattening, and attentional impairment; and (3) disorganization – bizarre
behavior, positive thought disorder, and inappropriate affect. All
individuals with schizophrenia were taking antipsychotic medications at the time of participation in the study. For both control
and schizophrenia participants, the Structured Clinical Interview
for the DSM-IV-TR (45) was also used to determine criteria for
lifetime substance abuse/dependence diagnoses and rule-out any
current SA. Past SA was defined as a period longer than 6 months
without any SA or complications from abuse, determined by selfreport during the DSM-IV-TR diagnostic interview and other
reliable clinical sources (e.g., psychiatric records and/or personal
references).
TASKS AND MATERIALS

n-back version A

The first WM task was a two-back version of an n-back using
either words or faces (unfamiliar). The two-back version was used
because of previous literature indicating this level of WM processing elicits peak activation in schizophrenia patients compared to
healthy controls (48). We did not use a three-back level because
of concerns that it would exceed capacity limits for many patients
and thus would not provide valid estimates of WM-related brain
activation in patients. We could have also used a one-back condition, but were concerned that this would not be sufficiently
taxing. There were three runs with words and three runs with
faces. The words were concrete English nouns one to four syllables in length. The unfamiliar faces were neutral in emotion and
included both male and female genders. These same stimuli have
been used in a number of previous studies (49–52). Prior to each
run, participants watched a video that was either neutral (once
for words and once for faces), pleasant (once for words and once
for faces), or unpleasant (once for words and once for faces), with
the order counterbalanced across subjects. The videos were identical to those used in previous investigations (53), and consisted
of 9–10 min digitally presented (QuickTime format, resolution
320 × 240) video clips from comedy, documentary, and horror
movie genres (54). Headphones were utilized to enable participants to hear video-audio and dampen scanner noise. The effect
of the videos on performance was not of interest in the current
study, and therefore all analyses were collapsed across video conditions. In each run, participants were instructed to press the target
button if the current stimulus on the screen matched the stimulus
previously seen two trials back and to press the non-target button for any other stimuli presented on the screen. The sequence of
block events for this task included four initial fixation trials to allow
the signal to reach a steady-state, followed by 4 blocks of 16 twoback task trials (2.5 s stimulus presentations, 500 ms inter-stimulus
delays) interleaved with 4 blocks of 10 fixation trials displaying a
continuous cross-hair.
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n-back version B

For the second scanning session on a different day, participants
performed six additional runs of a two-back task, three with words
and three with unfamiliar faces. For this version of the n-back, the
unfamiliar faces were displaying either happy, fearful, or neutral
expressions (55, 56) and the word stimuli were neutral, positive, or
negative. The face stimuli matched in lighting, location, distance,
and exposure. Participants were provided the same instructions
as in the first two-back task described above. The sequence of
block events for this task included four initial fixation trials to
allow the signal to reach a steady-state, followed by 3 blocks of 32
two-back task trials (2.5 s stimulus presentations, 500 ms interstimulus delays) interleaved with 4 blocks of 16 fixation trials
displaying a continuous cross-hair. Task blocks either included
all neutral stimuli, 16 neutral and 16 positive stimuli, or 16 neutral
and 16 negative stimuli. As with the video task, the influence of
the emotional valence of the stimuli on performance was not of
interest in the current study, and all analyses were collapsed across
emotion type. Visual stimuli were generated by a G3 Macintosh
computer and PsyScope, and projected onto a computer screen
behind the subject’s head within the imaging chamber. Participants saw the screen through a mirror positioned approximately
8 cm above their face.
fMRI IMAGE ACQUISITION AND PROCESSING

Functional scanning was performed on a 3-T Siemens Allegra head-dedicated system at the Research Imaging Center
of the Mallinckrodt Institute of Radiology at the Washington
University Medical School. First, a low resolution 3D sagittal T1-weighted MP-RAGE acquisition image was obtained
(TE = 2.9 ms, TR = 6.6 ms, flip angle = 8°, 96 × 128 acquisition
matrix, 1 acquisition, 80 slices, 2 mm × 2.67 mm × 2 mm voxels). This MP-RAGE was then warped to Talairach space (57).
Second, a T2 image was subsequently acquired in the same position as the blood-oxygenation-level-dependent (BOLD) images
(TE = 96 ms, TR = 5 s, 189 × 256 acquisition matrix, 48 slices,
1.02 mm × 1 mm × 3 mm voxels), and used as a bridge to facilitate the registration of the T1-weighted images acquired during
the structural imaging session and the functional (T2*-weighted)
images. The slice locations for functional images were placed
based on the results of the computerized slice pre-registration.
The functional images were collected in runs using an asymmetric spin-echo echo-planar sequence sensitive to BOLD contrast
(T2*) (TR = 3000 ms, TE = 25 ms, FOV = 205 mm, flip = 90°).
During each functional run, sets of 32 contiguous axial images
with isotropic voxels (4 mm3 ) were acquired parallel to the
anterior–posterior commissure plane.
MR data were reconstructed into images, and normalized across
runs by scaling whole-brain signal intensity to a fixed value (mode
of 1000), and removing the linear slope on a voxel-by-voxel basis
to counteract effects of drift. To correct for head motion, the
images were aligned using six parameter rigid-body rotation and
translation correction algorithms (58, 59). The images were then
registered to a common Talairach atlas space (57) using 12 parameter linear (affine) transformations of the participant’s average
MP-RAGE structural image warped into T2 space, and then using
the T2 image to register the T2* and T1 images. Finally, the
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normalized, registered fMRI images were spatially smoothed with
a 9-mm FWHM Gaussian kernel.
STATISTICAL ANALYSIS

Behavioral data

To investigate the effects of past SA on WM accuracy performance
in schizophrenia patients and controls on both versions A and B of
the n-back, we used a repeated measures design implementing a
General Linear Model (GLM) executed in SPSSv19. These analyses
included stimulus type (words vs. faces) as a within subject factor
and diagnostic group (schizophrenia vs. controls) and past SA (no
vs. yes) as between-subject factors, with mean WM accuracy as the
dependent variable.
fMRI data

For the functional imaging data, GLMs were modeled within
each participant to estimate voxel-wise magnitudes of task-related
activity, with one GLM for each of the two n-back tasks. Each
GLM included regressors for linear trends within runs and baseline
shifts between runs computed for every subject. BOLD responses
to each block-type (e.g., words and faces) were modeled as “boxcar” functions, and then convolved with a canonical hemodynamic
response function to generate separate estimates for each condition. For clarity and brevity, only the main effects and interactions
involving past SA (e.g., main effects of past SA and diagnostic
group, and the past SA × diagnostic group interaction) were considered when examining differences in activations during each
WM task independently. Using an in-house software program
(FIDL), estimated GLMs from each individual participant were
then entered into whole-brain voxel-wise mixed effects analyses
of variance (ANOVA) using stimulus type (words vs. faces) as the

within subject factor, diagnostic group (control vs. schizophrenia)
and past SA (no vs. yes) as between-subject factors, and subjects
as a random factor.
Because our goal was to examine brain regions that showed
consistent associations with past SA, we focused on identifying
brain regions that showed the same effects across both versions A
and B of the two-back tasks. Replicating across WM functioning
between the two tasks was also done to increase confidence in our
findings of WM-related brain activation and to weaken any effects
specific to either the n-back version A or the n-back version B.
To do so, we thresholded the whole-brain statistical maps for the
n-back version A and the n-back version B at Z > 2.5 and k = 13
based on Monte Carlo simulations, and created conjunction maps
of regions showing the same effects across both tasks. Monte Carlo
simulations were utilized to protect against inflated type 1 error
(60, 61). This combination provides p < 0.05 whole-brain false
positive protection for inferences regarding brain regions showing
effects across both tasks. We then used planned contrasts in these
regions to clarify the direction of effects and to address the influence of any potential confounding variables that may covary with
past SA.

RESULTS
DEMOGRAPHIC CHARACTERISTICS

Overall, the schizophrenia patients and controls did not significantly differ in age, gender, ethnicity, handedness, or highest
parental education. However, the mean number of years of education was higher in the control group, and the rate of smoking
was higher for the schizophrenia group. With regard to subgroup
differences (see Table 1), controls with past SA were significantly

Table 1 | Demographic characteristics and clinical characteristics of participants.
Characteristic

Schizophrenia
SCZ

SCZ + SA

(n = 20)

(n = 17)

Age (years)

35.85 (8.28)

38.76 (10.23)

Gender (% male)

11 (55%)

14 (82%)

African American

11 (55%)

8 (47%)

Caucasian

Ethnicity (%)

Controls
t or χ2

p

CON

CON + SA

(n = 20)

(n = 12)

−0.95

0.345

32.65 (10.67)

42.08 (8.67)

3.13

0.094

13 (65%)

8 (67%)

0.23

0.746
9 (45%)

6 (50%)

t or χ2

p

−2.58

0.015

0.01

1.000

0.07

1.000

0.427

9 (45%)

9 (53%)

11 (55%)

6 (50%)

Handedness

62.50 (57.15)

51.47 (58.54)

0.57

0.567

76.50 (31.54)

62.08 (56.10)

0.81

Education (years)

13.10 (2.70)

13.00 (1.96)

0.12

0.900

16.22 (4.78)

14.70 (3.09)

0.97

0.335

Parental education (years)

13.66 (3.56)

14.42 (2.62)

−0.67

0.508

13.85 (2.32)

11.66 (1.61)

2.85

0.008

Smoker (% yes)

9 (45%)

13 (76%)

3.77

0.092

2 (10%)

3 (25%)

Positive symptoms rating

1.25 (1.37)

1.91 (1.31)

−1.49

0.144

0.00 (0.00)

0.04 (0.15)

1.28

0.338

−1.00

0.341

Negative symptom rating

1.85 (1.03)

1.83 (0.78)

0.03

0.970

0.25 (0.36)

0.27 (0.20)

−0.19

0.850

Disorganization symptoms rating

0.81 (0.72)

1.33 (0.79)

−2.06

0.046

0.38 (0.36)

0.60 (0.59)

−1.13

0.275

Age of onset (years)

18.30 (7.45)

19.88 (7.95)

−0.62

0.537

–

–

–

–

1.80

0.406

–

–

–

–

Antipsychotic mediations
Atypical

16 (80%)

15 (88%)

Typical

2 (10%)

2 (12%)

Combination atypical/typical

2 (10%)

0 (0%)

SCZ, schizophrenia patients; SCZ + SA, schizophrenia patients with past substance abuse; CON, control participants; CON + SA, control participants with past
substance abuse.
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Table 3 | Accuracy during the working memory tasks.

Table 2 | Past substance use diagnostic characteristics of the
schizophrenia and control participants.

Group
t or χ2

n-Back version A

n-Back version B

Substance use

SCZ + SA

CON + SA

characteristics

(n = 17)

(n = 12)

Word

Face

Word

Face

N (%)

N (%)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

–

5 (41.7%)

Alcohol only diagnosis

8.55

p

0.007

CON

0.91 (0.08)

0.93 (0.06)

0.97 (0.02)

0.93 (0.04)

0.91 (0.09)

0.91 (0.08)

0.95 (0.03)

0.92 (0.05)

Alcohol

11 (64.7%)

9 (75%)

0.34

0.694

CON + SA

Cannabis

11 (64.7%)

4 (33.3%)

2.77

0.139

SCZ

0.88 (0.07)

0.86 (0.08)

0.91 (0.07)

0.85 (0.14)

Cocaine

3 (17.6%)

4 (33.3%)

0.94

0.403

SCZ + SA

0.85 (0.05)

0.84 (0.08)

0.90 (0.06)

0.84 (0.06)

Hallucinogen

3 (17.6%)

1 (8.3%)

0.51

0.622

Stimulant

2 (11.8%)

0

1.51

0.498

Opiate

1 (5.9%)

0

0.73

1.000

Sedative

2 (11.8%)

0

1.51

0.498

Polysubstance

3 (17.6%)

1 (8.3%)

0.51

0.622

Number of dependence

15 (88.2%)

7 (58.3%)

3.43

0.092

14 (82.4%)

5 (41.7)

5.15

0.046

–

–

5.85

0.211

1 Diagnosis

3 (17.6)

7 (58.3)

–

–

2 Diagnoses

8 (47.1)

3 (25)

–

–

3 Diagnoses

4 (23.5)

2 (16.7)

–

–

4 Diagnoses

1 (5.9)

0

–

–

5 Diagnoses

1 (5.9)

0

–

–

diagnoses
More than one substance
use diagnosis
Number of substance use
diagnoses

SCZ + SA, schizophrenia patients with past substance abuse; CON + SA, control
participants with past substance abuse. Alcohol through polysubstance includes
both abuse and dependence diagnoses.

older than the controls without past SA (t = −2.58, p = 0.015). In
addition, controls without past SA had parents with significantly
higher levels of education compared to the parents of controls
with past SA (t = 2.85, p = 0.008). Subsequently, age and highest parental education were entered into secondary behavioral
and fMRI analyses as confounding variables. No significant differences emerged between the schizophrenia patients with and
without past SA, with the exception of the schizophrenia patients
with past SA having slightly higher disorganized symptomology
(t = −2.06, p = 0.046). Past SA was not correlated with neither
positive symptoms (r = 0.24, p = 0.145) nor negative symptoms
(r = 0.01, p = 0.970) in the schizophrenia patients. Specific past
SA characteristics for the subgroups of control and schizophrenia
participants are presented in Table 2.
WORKING MEMORY ACCURACY

A significant main effect of diagnostic group for the n-back version A (F = 11.45, p = 0.001) and n-back version B (F = 13.94,
p = < 0.001) was observed, such that schizophrenia patients were
significantly less accurate than controls (see Table 3). There was,
however, no significant main effect of past SA for either the n-back
version A (F = 0.92, p = 0.340) or n-back version B (F = 0.58,
p = 0.446), nor was there a significant diagnostic group by past SA
interaction for either the n-back version A (F = 0.01, p = 0.894)
or n-back version B (F = 0.06, p = 0.807).
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SCZ, schizophrenia patients; SCZ + SA, schizophrenia patients with past substance abuse; CON, control participants; CON + SA, control participants with past
substance abuse.

fMRI RESULTS

As described above, we used voxel-wise mixed effects ANOVAs
with diagnostic group and past SA as between-subjects factors
and stimulus type as a within subject factor to analyze differences in activation that replicated across both versions A and B
of the n-back. We focused on regions that displayed significant
main effects or interactions with group and/or past SA. First,
as shown in Table 4, several regions engaged during both versions of the n-back demonstrated a significant main effect of
diagnostic group. When compared to the control participants,
schizophrenia patients displayed significantly greater WM-related
activation in the left superior temporal gyrus, left superior parietal
lobule, left cerebellum tonsil and pyramis, and the right supramarginal gyrus. Second, there were a few regions that demonstrated
a significant main effect of a past SA (see Table 4). During
the n-back version A and n-back version B, the participants
with past SA displayed increased activation in the left superior
temporal gyrus, left middle temporal gyrus, and the left angular gyrus while participants without past SA were deactivating
these same regions. Participants with past SA also deactivated the
left posterior cingulate gyrus less than participants without past
SA.
A number of regions showed significant activation differences across both versions of the n-back tasks as a function of
the interaction of diagnostic group and past SA (see Figure 1;
Table 5). Subsequent analysis with planned contrasts to follow
up on the sources of these interactions revealed that they largely
reflected robust differences across both versions of the n-back
tasks between controls with and without past SA (see Table 5).
These regions included the left superior frontal gyrus, left DLPFC,
left fusiform, left insula, left anterior/middle cingulate cortex, left
thalamus, right orbitofrontal gyrus, right precentral gyrus, right
inferior parietal lobule, and the bilateral middle frontal gyrus.
With the exception of the right inferior parietal lobule during
the n-back version A, these fronto-partial-thalamic regions activated significantly more in the controls with past SA relative to
controls without past SA. Also seen in Table 5, relatively few
regions displayed significant differences between the schizophrenia patients with and without past SA (e.g., bilateral middle frontal
gyrus and the right interior parietal lobule). During only the
n-back version A, the schizophrenia patients with past SA demonstrated significantly less activation in these three regions compared
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Table 4 | Brain regions showing main effects of diagnostic group and past substance abuse during both versions of the n-back.
Region

BA

x

y

z

z-Value
n-Back

n-Back

version A

version B

Activity pattern
n-Back version A

n-Back version B

MAIN EFFECT OF DIAGNOSTIC GROUP (CONTROL VS. SCHIZOPHRENIA)
L superior temporal gyrus

22

−64

−32

13

2.92

3.66

CON(−) < SCZ

CON(−) < SCZ

L superior parietal lobule

7

−32

−46

62

3.15

3.43

CON < SCZ

CON < SCZ

L cerebellum tonsil

−

−33

−48

−34

2.98

3.63

CON < SCZ

CON < SCZ

L cerebellum pyramis

−

−43

−71

−31

3.26

3.57

CON < SCZ

CON < SCZ

R supramarginal gyrus

40

63

−38

29

2.85

2.92

CON(−) < SCZ

CON(−) < SCZ

MAIN EFFECT OF PAST SUBSTANCE ABUSE (NO VS. YES)
L superior temporal gyrus

22

−63

−17

2

2.73

2.96

NSA(−) < SA

NSA(−) < SA

L middle temporal gyrus

21

−65

−37

−12

3.04

3.71

NSA(−) < SA

NSA(−) < SA

L angular gyrus

39

−49

−61

38

2.80

2.91

NSA(−) < SA

NSA(−) < SA

L posterior cingulate

31

−7

−44

38

2.64

3.28

NSA(−) > SA(−)

NSA(−) > SA(−)

Activity patterns are activations, except when denoted with (−), indicating deactivation. Coordinates (x, y, z) reflect Talairach template space (57). BA, Brodmann
area; L, left; R, right; CON, all control participants; SCZ, all schizophrenia patients; NSA, all participants without past substance abuse; SA, all participants with past
substance abuse.

FIGURE 1 | Working memory-related brain regions demonstrating a significant interaction between diagnostic group and past substance abuse. Note:
all regions replicated across both n-back tasks, as described in the text. Brain slices are shown with the right hemisphere on the right side.

to patients without past SA (see Figure 2). All the aforementioned main effects and interaction results remained significant
in secondary analyses when age and highest parental education
were included as confounding variables. Thus, results presented
throughout were from the original analyses not covarying for these
variables.
POST HOC ANALYSES COMPARING SCHIZOPHRENIA AND CONTROLS
WITHOUT PAST SA

A number of regions showing interactions between diagnostic
group and past SA in this study are those who have been similarly

Frontiers in Psychiatry | Schizophrenia

identified as showing group differences during WM and executive
function tasks in prior studies (62). Thus, we wanted to examine if these regions would show diagnostic group differences if we
compared the schizophrenia patients without past SA to the controls without past SA (the typical sample composition in imaging
studies within schizophrenia). As shown in Table 6, most of these
regions showed significant group differences across both n-back
tasks, with the exception of the DLPFC. The schizophrenia patients
without past SA displayed significantly greater activation compared to controls without past SA. Although a few regions were no
longer significantly different (e.g., bilateral middle frontal gyrus
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Table 5 | Brain regions displaying a significant interaction between diagnostic group and past substance abuse during both versions of the
n-back.
Region

BA

x

y

z

z-Value
n-Back

n-Back

version A

version B

Activity pattern
n-Back version A

n-Back version B

GROUP (CONTROL VS. SCHIZOPHRENIA) × PAST SUBSTANCE ABUSE (NO VS. YES)
L superior frontal gyrus

8

0

29

53

3.54

4.48

C(−) < CSA

S = SSA

C(−) < CSA

S = SSA

L DLPFC

9

−40

31

27

2.75

3.21

C < CSA

S = SSA

C < CSA

S = SSA

L middle frontal gyrus
L fusiform gyrus

6

−35

10

54

3.26

2.84

C(−) < CSA

S > SSA(−)

C(−) < CSA

S = SSA

19

−49

−72

−10

3.04

3.27

C < CSA

S = SSA

C < CSA

S = SSA

L insula

13

−40

9

−3

3.03

3.34

C < CSA

S = SSA

C < CSA

S = SSA

L insula

13

−41

−7

5

2.80

2.67

C(−) < CSA

S = SSA

C < CSA

S = SSA

L ant./mid. cingulate

24

0

-6

36

3.71

3.03

C(−) < CSA

S = SSA(−)

C(−) < CSA

S = SSA

L thalamus

−

−9

−28

−4

2.57

2.77

C < CSA

S = SSA

C < CSA

S = SSA

R middle frontal gyrus

10

36

55

3

2.73

3.03

C(−) < CSA

S = SSA

C(−) < CSA

S = SSA

R middle frontal gyrus

6

36

8

58

3.20

2.97

C < CSA

S > SSA

C < CSA

S = SSA
S = SSA

R orbitofrontal gyrus

47

41

18

−2

2.68

3.60

C < CSA

S = SSA

C < CSA

R precentral gyrus

44

53

13

8

2.82

3.17

C < CSA

S = SSA

C < CSA

S = SSA

R inferior parietal lobule

40

41

−53

54

2.63

3.14

C = CSA

S > SSA

C < CSA

S = SSA

Activity patterns are activations, except when denoted with (−), indicating deactivation. Coordinates (x, y, z) reflect Talairach template space (57). “=”, represents no
significant difference in post hoc analysis; BA, Brodmann area; L, left; R, right; DLPFC, dorsolateral prefrontal cortex; ant., anterior; mid., middle; C, control participants
without past substance abuse; CSA, control participants with past substance abuse; S, schizophrenia patients without past substance abuse; SSA, schizophrenia
patients with past substance abuse.

FIGURE 2 | Graphs illustrating the differential effect of past
substance abuse across groups in WM-related brain activity. Note:
these graphs present magnitude estimates from follow up analyses of
the patterns of activation driving the interaction effect of diagnostic

and right inferior parietal lobule), most regions remained significantly different from controls when patients with past SA were
added to the sample of patients without past SA. Such results suggest that a differential history of past SA in schizophrenia samples
is not responsible for group differences from controls in functional
brain activity during WM tasks.

www.frontiersin.org

group and presence of past substance abuse. The three regions
presented were the only regions to show significant differences
between schizophrenia patients with and without past substance abuse
(see Table 4).

DISCUSSION
The goal of this initial investigation was to examine the effects of
past SA in schizophrenia patients compared to healthy controls.
This was accomplished by assessing both behavioral and neural
activity that replicated across two versions of a two-back WM task
in schizophrenia patients and controls with and without past SA.
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Table 6 | Post hoc analyses examining the source of interaction effects between diagnostic group and past substance abuse.
Region

BA

x

y

z

Activity pattern
CON (no past SA) vs.

CON (no past SA) vs. SCZ

SCZ (no past SA)

(with and without past SA)

n-Back

n-Back

version A

version B

n-Back version A

n-Back version B

L superior frontal gyrus

8

0

29

53

C < S***

C < S***

C < S+**

C < S+***

L DLPFC

9

−40

31

27

C=S

C=S

C = S+

C = S+

L middle frontal gyrus

6

−35

10

54

C < S**

C < S*

C = S+

C = S+

L fusiform gyrus

19

−49

−72

−10

C < S**

C < S*

C < S+**

C = S+

L insula

13

−40

9

−3

C < S**

C < S**

C < S+**

C < S+**

L insula

13

−41

−7

5

C < S*

C < S*

C < S+**

C < S+***

L ant./mid. cingulate

24

0

−6

36

C < S**

C < S***

C < S+***

C < S+***

L thalamus

−

−9

−28

−4

C < S***

C < S*

C < S+**

C < S+*

R middle frontal gyrus

10

36

55

3

C < S**

C < S***

C < S+**

C < S+*

R middle frontal gyrus

6

36

8

58

C < S**

C < S*

C = S+

C = S+

R orbitofrontal gyrus

47

41

18

−2

C < S*

C < S**

C = S+

C < S+**

R precentral gyrus

44

53

13

8

C < S*

C < S*

C < S+*

C < S+***

R inferior parietal lobule

40

41

−53

54

C < S*

C < S*

C = S+

C = S+

Results are from two-sample t-tests. Coordinates (x, y, z) reflect Talairach template space (57). “=,” represents no significant difference; BA, Brodmann area; L, left;
R, right; DLPFC, dorsolateral prefrontal cortex; ant., anterior; mid., middle; C, control participants without past substance abuse; S, schizophrenia patients without
past substance abuse; S+, combined schizophrenia patients with and without past substance abuse; *p < 0.05, **p < 0.01, ***p < 0.001.

Although we had predicted that schizophrenia patients with past
SA would demonstrate the highest level of WM impairment, our
results indicated that past SA did not exacerbate behavioral or
functional WM impairment in schizophrenia. An interesting differential effect of past SA was observed between controls and schizophrenia patients in WM-related brain functioning. Specifically,
a number of significant WM-related brain activation differences
were observed between controls with and without past SA, while
only a few regions showed significantly different task-related activation between schizophrenia patients with and without past SA.
These results remained significant after age and highest parental
education were considered as cofounding variables. The results are
discussed in more detail below.
As expected, the schizophrenia patients were significantly less
accurate than controls on both versions of the n-back. However, no significant differences in WM accuracy were observed
in either controls or schizophrenia patients with and without
past SA. These findings are consistent with other previous investigations observing equivalent or better neurocognitive performance in abstinent schizophrenia patients with past SA compared
to patients without past SA (25, 26, 63). In particular, a WM
and multi-tasking investigation reported by Thoma and Daum
(22) indicated no additive impact of past SA on WM deficits
in schizophrenia patients. There have been a few studies, however, of past SA in schizophrenia that have shown exacerbated
neurocognitive impairment (29, 30, 64). These differences may
be accounted for by the individual effects of the SA (29, 30, 64),
and/or inpatient samples with more severe neurocognitive impairments (64). Regarding the behavioral findings in the controls,
other fMRI investigations of WM have also reported comparable
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performances between controls with and without past SA (17,
19, 65).
Differential effects of past SA on WM-related brain functioning
were demonstrated between control and schizophrenia groups in
regions that showed a significant interaction with diagnostic group
and past SA. Subsequent investigation of these interaction patterns
indicated that past SA had the greatest impact in the control group,
with controls with past SA showing significant increased activation
compared to controls without past SA in a range of fronto-parietalthalamic regions that replicated across both versions of the n-back.
In contrast, the schizophrenia patients with and without past SA
only differed significantly in decreased WM-related activation in
the bilateral middle frontal gyrus and the right inferior parietal
lobule, only observed for version A of the n-back.
Our findings in the controls are consistent with previous studies showing residual SA-related abnormal increased activation in
frontal–parietal regions evoked during WM in long-term abstinent controls (17, 19, 20, 65). Interestingly, the frontal–parietal
brain regions whose activations were impacted by past SA in the
controls are an overlap of regions previously shown to be important for successful performance on the n-back (66). It could be that
the controls with past SA needed to recruit these frontal–parietal
regions to a greater degree than the controls without past SA in
order to maintain equivalent WM performance (Table 3).
The observation of a differential effect of past SA between the
controls and schizophrenia patients is consistent with some previous literature. Two neurocognitive studies also found a differential
effect of past SA when comparing schizophrenia and controls with
and without past SA (31, 32). These studies observed no deleterious impact of past SA in the schizophrenia groups with and
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without past SA, but did find that past SA was related to poorer
neurocognition in the controls with past SA compared to controls without past SA. In addition, Rentzsch and colleagues (40)
observed significant abnormal inhibitory brain functioning, measured by EEG, related to past cannabis abuse only in the control
group, while differences were not observed between schizophrenia
patients with and without past cannabis abuse.
Further regarding our findings showing schizophrenia patients
with past SA did not have a higher degree of WM impairment
compared to patients without past SA; it has been proposed
that schizophrenia patients with past SA have less neurocognitive impairments. This may be due to that fact that these patients
were less vulnerable to developing psychosis prior to SA (24). Others have suggested that schizophrenia patients with past SA may
have higher levels of cognitive functioning because some degree
of social skills and intact cognitive function are required to obtain
and maintain an addiction (2, 3, 67). In addition, schizophrenia
patients with past SA, compared to patients without past SA, tend
to show significantly higher levels of life satisfaction and executive
function skills related to better social functioning (68, 69), which
has not been observed in controls with past SA compared to controls without past SA (70–72). Other recent fMRI studies have also
provided findings that patients with past SA may have more intact
neurobiological functioning during cognitive performance compared to patients without past SA. Unlike patients without past
SA, patients with past SA have been shown to activate the medial
prefrontal cortex during social emotion processing (33) and affect
regulation (34). Løberg and colleagues (73) reported that patients
with past cannabis abuse showed increased activation in the effort
mode network and decreased activation in the default mode network during neurocognitive performance compared to patients
without past cannabis abuse. Similar to the decreased activation
differences observed between schizophrenia with and without past
SA in this study, Potvin et al. (74) also showed that patients
without previous cannabis abuse had decreased activation in the
left superior parietal gyrus during cognitive performance relative
to patients with previous cannabis abuse and healthy controls.
Indeed, it may be our results are reflecting subtly less WM-related
impairments in brain activation in schizophrenia patients with
past SA because of the necessity to have some level of executive
function to have previously obtained and maintained their SA,
though this should not in any way be construed as an endorsement
of substance use.
There are limitations that need to be considered in this initial
investigation. The first is the inclusion of participants with histories of abusing different types of substances. Different substances
may affect neurocognitive and brain functioning differently in
schizophrenia (3). An important direction for future examinations
of past SA is inclusion of samples of schizophrenia and control
participants with homogenous SA histories, though a much larger
sample size would be needed for this. A second limitation is examining the effect of past SA on only one domain of neurocognition.
Despite having the advantage of replicating across two versions of
the same WM task, these results should be interpreted with some
caution as other domains of neurocognition (e.g., attention, learning, and other types of memory) may be impacted differently by
past SA in schizophrenia. A third limitation is the cross-sectional
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nature of this investigation. Future research will benefit from longitudinal studies of SA in long-term abstinent patients by more
accurately capturing the trajectory of past SA in schizophrenia,
and if less impaired neurocognition is static as abstinence time
increases. Collecting information on family history of SA and
dosage of SA could also bolster future longitudinal studies examining the relationship between SA and neurocognitive impairment in
schizophrenia. Finally, because we did not do urine or hair screening for presence of substances, our results may be confounded by
the reliance on self-report of the absence of current SA.
In summary, we found a differential impact of past SA on
WM-related brain function in controls vs. schizophrenia patients.
Controls with past SA displayed increased WM-related brain activation in several frontal-parietal-thalamic regions relative to controls without past SA. In contrast, schizophrenia patients with and
without past SA only displayed differences in decreased activation
in the middle frontal gyrus and inferior parietal lobule during
only the n-back version A. These differential results are in the context of equivalent behavioral WM accuracy between control and
schizophrenia patients with and without past SA. These findings
are consistent with the suggestion in the literature that individuals
with schizophrenia who abuse substances may have fewer neurocognitive deficits (at least initially) due to social skills involved in
addiction maintenance (2, 67) and/or had less of a vulnerability to
develop psychosis prior to the introduction of abusive substances
(24). These preliminary findings of a differential impact of past SA
on WM brain functioning among the controls and schizophrenia
patients with and without past SA has important implications for
the continued understanding of neurobiological processes underlying neurocognitive impairment in schizophrenia patients with
and without comorbid SA.
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